Holen Sie sich die Stockscreener-App
0.00
0.00%
0.00
Schlusskurs vom Vortag:
$0.00
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
Marktkapitalisierung:
$N/A
Einnahmen:
$1.65M
Nettoeinkommen (Verlust:
$-5.91M
KGV:
0.00
EPS:
-0.1707
Netto-Cashflow:
$-3.03M
1W Leistung:
+0.00%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$0.00
Vitro Biopharma, Inc. Stock (VTRO) Company Profile
Firmenname
Vitro Biopharma, Inc.
Sektor
Branche
Telefon
(720) 859-4120
Adresse
4621 TECHNOLOGY DRIVE, GOLDEN
Compare VTRO vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTRO
Vitro Biopharma, Inc.
|
0.00 | 0 | 1.65M | -5.91M | -3.03M | -0.1707 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vitro Biopharma, Inc. Aktie (VTRO) Neueste Nachrichten
World In Vitro Transcription Enzyme MixesMarket Analysis, Forecast, Size, Trends and Insights - IndexBox
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits - Business Wire
Legend surges on early data for ‘in vivo’ lymphoma cell therapy - BioPharma Dive
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives - The Manila Times
How GT Biopharma is using AI to shrink drug timelines and costs - Stock Titan
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104Important Step in RHB-204 Development for MAP-related Crohn's Disease - PR Newswire
Boston meeting will spotlight Cue Biopharma's new autoimmune drug data - Stock Titan
VTRO (Vitro Biopharma) PB Ratio : 0.00 (As of Mar. 26, 2026) - GuruFocus
These 18 french biotech startups could shape tomorrow’s medicine - Labiotech.eu
Cue Biopharma to present new in vitro data for CUE-401 - TipRanks
Cue Biopharma unveils in vitro data for CUE-401 in autoimmune disease research - Traders Union
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 - The Manila Times
The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - BioInformant
Vitro Biopharma, Inc. Reports Earnings Results for the Full Year Ended October 31, 2025 - marketscreener.com
Best Biotech Stocks of 2026 and How to Invest in Them - The Motley Fool
How new approach methodologies are reshaping drug discovery - McKinsey & Company
Early bits of in vivo CAR-T human data emerge from biotech trials in China - Endpoints News
Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting - CRISPR Medicine News
Vitro Biopharma Launches New Products to Advance Breast Cancer Treatment - ACCESS Newswire
Vitro Biopharma Announces Early 2016 Results: Increased Revenue and Expansion Activities to Fuel Growth - ACCESS Newswire
The 16th international oncolytic virotherapy conference: from in vitro to clinical studies, novel approaches in cancer therapy meeting report - Frontiers
Vitro Biopharma | CORRESP: CORRESP - Moomoo
Dealmaking Quarterly Statistics, Q4 2024 - Citeline News & Insights
Stem Cell Therapy for the Coronavirus COVID-19 Pandemic - ACCESS Newswire
Closing the women’s health gap: Biopharma’s untapped opportunity - McKinsey & Company
Layoffs Continued Across Biopharma in 2024 - BioSpace
In Vitro Diagnostics (IVD) Market Size to Surpass USD 157.56 Billion by 2034 - BioSpace
Press Release Service: Be Biopharma Announces Preclinical Data for Novel Engineered B Cell Medicine for the Potential Treatment of Hypophosphatasia - CRISPR Medicine News
Vitro Biopharma(VTRO) Stock Options Chain | Quotes & News - Moomoo
Top 5 In-Vitro Diagnostics [IVD] Companies - Fortune Business Insights
A biotech working on a new approach to IVF raises $33M in fresh funding - BioPharma Dive
GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications - BioSpace
FDA defends lab test rule, as critics fear industry upheaval - BioPharma Dive
Asgard Therapeutics Snags €30M to Develop In Vivo Direct Cell Reprogramming Technologies for Cancer - BioInformant
Vitro Biopharma Company Profile & Introduction - Moomoo
EDGAR Filing Documents for 0001493152-24-004779 - SEC.gov
Pharmaceutical Industry Mergers & Acquisitions Roundup - Contract Pharma
Vitro Biopharma(VTRO) Stock Price Today | Quotes & News - Moomoo
Matinas BioPharma Demonstrates in vivo Biological Activity - GlobeNewswire
Vitro Biopharma, Inc. announced a financing transaction - marketscreener.com
Vitro Biopharma, Inc. (VTRO) Stock Live Price, Chart & News - CoinCodex
Experience real-time quotes, in-depth charts, and analyst ratings - webull.com
VTRO IPO NewsStem cell biotech Vitro Biopharma sets terms for $10 million IPO - renaissancecapital.com
The Next Normal – The future of biotech: AI-driven drug discovery - McKinsey & Company
FUJIFILM Irvine Scientific PRIME-XV Stem FreezIS DMSO-Free Cryopreservation Medium to be Used in FDA-Authorized Clinical Trial - Business Wire
Foundation Medicine and Day One Biopharmaceuticals Announce Global Collaboration to Advance Pediatric Cancer Care - Business Wire
GT Biopharma Poster Presentation and Mini Oral Session at - GlobeNewswire
Vitro Biopharma, Inc. has filed an IPO in the amount of $17.25 million. - marketscreener.com
Biotech - McKinsey & Company
Business of Biotechniques 2022 - BioTechniques
Developing A Robust In Vitro Intestinal Model For Preclinical Candidate Screening Of GI Toxicity - Pharmaceutical Online
Finanzdaten der Vitro Biopharma, Inc.-Aktie (VTRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
Kapitalisierung:
|
Volumen (24h):